Stroke, Vol 23, 703-711, Copyright © 1992 by American Heart Association
RN Willette, CF Sauermelch, R Rycyna, S Sarkar, GZ Feuerstein, AJ Nichols and EH Ohlstein
BACKGROUND AND PURPOSE: Platelet-fibrin thrombi in the lumen of
atherostenotic carotid arteries may underlie transient ischemic attacks and
cerebral infarction. For this reason, we investigated the antiplatelet and
antithrombotic effects of a novel and potent platelet fibrinogen receptor
(glycoprotein IIb/IIIa) antagonist (SK&F 106760). METHODS: The effects
of 0.1-3.0 mg/kg i.v. SK&F 106760 on platelet aggregation were examined
ex vivo in canine platelet-rich plasma (n = 20). In addition, the
antithrombotic effects of SK&F 106760 were compared with those of
aspirin in an acute canine model of extracranial carotid artery thrombosis
with high-grade stenosis. Sham-operated (n = 4), vehicle-treated (n = 6),
SK&F 106760-treated (n = 8), aspirin- treated (n = 9), and SK&F
106760+aspirin-treated (n = 5) dogs were examined. RESULTS: The intravenous
administration of SK&F 106760 caused a dose-related inhibition of ex
vivo platelet aggregation. In the carotid artery thrombosis model, an
occlusive thrombus formed at stenotic sites in the region of the carotid
bifurcation. The thrombogenic process caused a progressive reduction in
carotid blood flow and reduced the cortical microvascular perfusion and
electroencephalographic power. Based on nuclear magnetic resonance
spectroscopy, the occlusive events depleted the stores of high-energy
phosphates (adenosine triphosphate and phosphocreatine) and increased the
lactate concentration in the forelimb somatosensory area of the parietal
cortex. In this model, the administration of 1 mg/kg i.v. SK&F 106760
prevented thrombosis of the stenotic carotid artery. Consequently,
neurophysiological, cerebral hemodynamic, and metabolic parameters were all
improved significantly in the SK&F 106760-treated group. No dog
receiving SK&F 106760 reoccluded during the 1-hour posttreatment
observation period. In contrast, thrombosis of the carotid artery was
associated with neurophysiological deterioration in six of the nine dogs
treated with 5 mg/kg i.v. aspirin. Both spontaneous and evoked (increased
carotid stenosis) aspirin-resistant thrombosis were abolished by SK&F
106760 treatment. CONCLUSIONS: These results suggest that antagonism of
fibrinogen binding to platelet glycoprotein IIb/IIIa (the final common
pathway for aggregation) may represent a new and more effective
antithrombotic approach to the treatment of cerebral transient ischemic
attacks and infarction associated with extracranial carotid artery disease.
ARTICLES
Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa. 19406-0939.
This article has been cited by other articles:
![]() |
L. G. Frederick, O. D. Suleymanov, J. A. Szalony, B. B. Taite, A. K. Salyers, L. W. King, L. P. Feigen, and N. S. Nicholson Protective Effect of Oral Xemilofiban in Arterial Thrombosis in Dogs : Increased Activity in Combination With Aspirin Circulation, August 25, 1998; 98(8): 813 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Rebello, E. M. Driscoll, and B. R. Lucchesi TP-9201, A Glycoprotein IIb/IIIa Platelet Receptor Antagonist, Prevents Rethrombosis After Successful Arterial Thrombolysis in the Dog Stroke, September 1, 1997; 28(9): 1789 - 1796. [Abstract] [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |